This inventor holds 2 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 1 EPO patent. Top assignee: H Bion Co., Ltd.. Active years: 2014-2016.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014-2016
Title: Ja-Min Koo: Innovator in Stem Cell Research
Introduction
Ja-Min Koo is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of stem cell research, particularly in the development of embryonic stem cell lines. With a total of 2 patents, his work is paving the way for advancements in regenerative medicine.
Latest Patents
Ja-Min Koo's latest patents include groundbreaking innovations in the production of neuro-progenitor cells. One of his patents describes a neuro-progenitor produced from an SCNT-derived embryonic stem cell line. This line is derived from a nucleus-transferred oocyte, which is prepared by transferring the nucleus of a human somatic cell into an enucleated human oocyte. This process allows for the differentiation into various desired cell types. Another patent focuses on a human embryonic stem cell line prepared by the same nuclear transfer method, emphasizing its potential to differentiate into multiple cell types.
Career Highlights
Ja-Min Koo is associated with H Bion Co., Ltd., where he continues to advance his research in stem cell technology. His work is crucial in exploring the therapeutic applications of stem cells in treating various diseases.
Collaborations
Some of his notable coworkers include Sung-Il Roh and Woo-Suk Hwang, who are also recognized figures in the field of stem cell research.
Conclusion
Ja-Min Koo's innovative work in stem cell research and his contributions to the development of embryonic stem cell lines highlight his role as a leading inventor in this vital area of science. His patents reflect a commitment to advancing medical science and improving therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile